Quest Diagnostics (DGX) traded down -0.16 % during a 24 hours period ending at 12:29 PM Central Europe on Wednesday 28th. One Quest Diagnostics stock can currently be bought for about USD 242.56 on popular exchanges. Current supply of Quest Diagnostics stocks is 110.4 mn. Quest Diagnostics has a current market capitalization of USD 26.8 bn and approximately USD 222.9 mn worth of Quest Diagnostics was traded on exchanges in the last 24 hours. Since last month end, Quest Diagnostics has traded 2.08 % up. Simple moving average of last 200 days is at USD 211.11. The highest price of past 52 weeks was recorded at USD 248.84 on 09/21/2026. 52 weeks low was at USD 171.18 on 01/05/2026.
Summary of the latest news for Quest Diagnostics
Quest Diagnostics Inc. has experienced notable growth in its share price over the past three years, with recent market activity reflecting a significant appreciation for investors who entered early. The company’s shares, traded on the NYSE, moved from a close near $128 in October 2023 to a recent closing level approaching $243, indicating a substantial rise in value. This performance has contributed to an overall market capitalization in the mid‑$26 billion range. While the report does not detail specific earnings or dividend policy, it highlights the company’s steady upward trajectory and the potential benefits for long‑term shareholders. No additional financial metrics or operational updates were included in the source material.
Here is how related stocks have performed in the past 24 hours:
Credo Holdi (CRDO) traded up 10.77 % and now trades at USD 167.43. Current market capitalisation for Credo Holdi is USD 31.2 bn. Credo Holdi has a current price to earnings ratio of 57.98.
Cheniere Energy (CQP) traded down -0.77 % and now trades at USD 65.76. Current market capitalisation for Cheniere Energy is USD 31.9 bn. Cheniere Energy has a current price to earnings ratio of 12.05. Cheniere Energy Partners LP announced its latest quarterly dividend, noting a forward yield that reflects its current valuation stance. The company reiterated its commitment to returning value to shareholders through regular dividend payments. The announcement underscores Cheniere’s ongoing strategy to balance cash flow generation with growth initiatives in the energy sector.
Huntington Bancshares (HBAN) traded down -0.13 % and now trades at USD 15.71. Huntington Bancshares has a market capitalisation of USD 31.7 bn. Huntington Bancshares has a current price to earnings ratio of 12.88. Huntington Bancshares Inc. reported its third‑quarter 2026 results in a Form 10‑Q filing released on October 27. The bank’s net interest income rose by roughly thirty‑seven percent compared with the same period last year, driven mainly by a sizable increase in earning assets following the acquisitions of Cadence Bank and Veritex Holdings. Net income attributable to Huntington fell to about $721 million, or $0.33 per diluted share, after an impact of acquisition‑related expenses that reduced earnings by about $0.05 per share. The company’s total assets increased by more than twenty‑five percent, largely reflecting the Cadence transaction, while loan‑loss provisions and non‑performing assets rose in line with the expanded loan portfolio. Credit quality metrics, including the allowance for credit losses, remained within the company’s moderate‑to‑low risk tolerance, and the capital ratios stayed above regulatory thresholds, supporting a continued emphasis on disciplined growth and shareholder returns.
Ge Healthcare (GEHC.MX) traded up 0.04 % and now trades at USD 71.11. Ge Healthcare has a market capitalisation of USD 32.1 bn. Ge Healthcare has a current price to earnings ratio of 16.6. GE HealthCare Technologies is set to announce its latest quarterly results on October 28 2026. Analysts project earnings per share slightly above the prior year’s figure, with expectations that revenue will have grown modestly compared with the same period last year. The company’s guidance for the full fiscal year suggests a continuation of this upward trend, with analysts anticipating an improvement in earnings and revenue over the previous year’s performance. The announcement will provide further detail on the company’s financial trajectory and operational progress.
About Quest Diagnostics
Quest Diagnostics Incorporated is a health care provider operating a national network of full-service laboratories, rapid response laboratories, and patient service centers. The company specializes in offering esoteric, routine medical, drugs of abuse, and non-hospital-based anatomic pathology testing services. You can find more information about their offerings on their website, www.questdiagnostics.com , and they are listed on the New York Stock Exchange. Their initial public offering date was December 17, 1996.